News
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research recommends buying APONTIS PHARMA AG shares with a target price of €17 after solid H1/24 results and positive outlook. Analyst Christian Orquera maintains his BUY rating -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: KWS SAAT SE & Co. KGaA: Based on preliminary key figures, KWS significantly exceeds forecasts for fiscal year 2023/2024 and publishes outlook for fiscal year 2024/2025
KWS SAAT SE & Co. KGaA significantly exceeds forecasts for fiscal year 2023/2024 and provides outlook for fiscal year 2024/2025. High sales and EBIT growth reported -
-
COMMUNIQUÉ DE PRESSE
Annual General Meeting of SGT German Private Equity paves the way for the renaming into The Payments Group Holding and the acquisition of three internet payment service providers
SGT German Private Equity AGM approves renaming to The Payments Group Holding & acquisition of 3 internet payment service providers. Transaction volume: 140M EUR in 2025. Revenue: 15M EUR -
-
COMMUNIQUÉ DE PRESSE
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Annonce du nombre d'actions et de droits de vote de Poxel, une société biopharmaceutique spécialisée dans les traitements contre les maladies métaboliques. Toutes les informations réglementées sont disponibles sur leur site web -
